<DOC>
	<DOCNO>NCT00482677</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy together temozolomide may kill tumor cell . It yet know whether radiation therapy temozolomide effective radiation therapy alone treat glioblastoma multiforme . PURPOSE : This randomized phase III trial study radiation therapy temozolomide see well work compare radiation therapy alone treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Radiation Therapy With Without Temozolomide Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival rate older patient newly diagnose glioblastoma multiforme treat short-course radiotherapy without temozolomide . Secondary - Compare progression-free survival patient treat regimen . - Compare nature , severity , frequency adverse event patient treat regimen . - Compare quality life patient treat regimen . - Determine methylation status O6-methylguanine-DNA methyltransferase promoter . OUTLINE : This multicenter , randomize study . Patients stratify accord center , age ( 65-70 year v 71-75 year vs ≥ 76 year ) , ECOG performance status ( 0-1 v 2 ) , extent resection surgery ( biopsy v complete incomplete resection ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo radiotherapy daily day 1-5 , 8-12 , 15-19 absence disease progression unacceptable toxicity . - Arm II : Patients undergo radiotherapy arm I receive oral temozolomide daily day 1-25 . Beginning 4 week completion radiotherapy temozolomide , patient receive adjuvant oral temozolomide daily day 1-5 . Treatment temozolomide alone repeat every 28 day 12 month absence disease progression unacceptable toxicity . Patients complete quality life questionnaire baseline periodically study treatment . Tissue sample collect baseline analyze methylation status O6-methylguanine-DNA methyltransferase promoter . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically confirm glioblastoma multiforme Grade IV disease WHO classification Newly diagnose disease Initial diagnostic surgery biopsy perform within past 4 week Not candidate standard radiotherapy ( 60Gy/30 fraction 6 week ) combination temozolomide PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN ALT AST &lt; 2.5 time ULN No known hypersensitivity temozolomide compound similar chemical composition temozolomide No history malignancy except adequately treat nonmelanoma skin cancer , curatively treated situ cancer cervix , curatively treat solid tumor evidence disease least 5 year No serious active infection ( e.g. , wound infection require parenteral antibiotic ) serious underlie medical condition would preclude study treatment No condition ( e.g. , psychological geographical ) would preclude study compliance PRIOR CONCURRENT THERAPY : No prior chemotherapy No prior radiotherapy No prior concurrent investigational therapy No concurrent surgical procedure tumor debulking No concurrent stereotactic boost radiotherapy No concurrent chemotherapy , immunotherapy , biological therapy No concurrent epoetin alfa Concurrent corticosteroid allow provided patient stable decrease dose least 14 day</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>